Future Growth of Subcutaneous Biologics Market | Top Key Players – Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Ltd., Takeda Pharmaceutical Company Ltd
Get a Request Sample of Research Report @ www.coherentmarketinsights.com/insight/request-sample/74
The disease also affects nearly 300,000 children in the U.S. according to RheumatoidArthritis.org. In the European region, EU-5 countries (Germany, France, United Kingdom, Italy and Spain) are the most potential market owing well established economy of these regions. Convenient drug delivery format is also in demand in developing regions such as Asia Pacific and Latin America where therapy compliance is a major issue. Large undiagnosed population, inadequate access to medicines and affordability issues hinder the market growth for subcutaneous biologics in developing regions.
The subcutaneous route of administration offers significant advantages over intravenous administration such as ease of drug administration, does not require skilled personnel for drug administration, enables at-home drug delivery and thus reduces patient time at healthcare facilities, reduced medicine cost and increased therapy compliance. Owing to aforementioned factors, the subcutaneous route of administration has gained enormous traction in recent years. Subcutaneous route of drug administration are highly effective in administering biologics such as vaccines, proteins, peptides, antibodies and other large and complex molecules.
Biologic, also known as biopharmaceutical, is a complex medicinal product manufactured by a biological process. Examples of biologics include blood and plasma derived products, vaccines, somatic cells and body proteins. Biologics market refers to a multibillion dollar opportunity that is expanding globally at an impressive growth rate. Most biologic products are given intravenously. However, in the past few years, a number of biologics have been developed that are given subcutaneously.
Humira (Adalimumab), MabThera/Rituxan (Rituximab), Zytux (Rituximab), Stelara (ustekinumab), Enbrel (Etanercept)., Neulasta (filgrastim), ORENCIA (abatacept), RoACTEMRA (tocilizumab) and Herceptin (Trastuzumab) are among the major commercially available biologics that are administered through subcutaneous route. F. Hoffmann-La Roche AG announced the European Commission (EU) approval of its subcutaneous formulation of RoACTEMRA (tocilizumab) in April 2014.
For More Information On This Report, Please Visit @ https://www.coherentmarketinsights.com/ongoing-insight/subcutaneous-biologics-market-74
Amgen launched Neulasta delivery kit in 2015 to automate the delivery of drug and preventing infection in cancer patients. The global market for subcutaneous biologics has been segmented by the aforementioned biologic brands.
Some of the major companies operating in the global subcutaneous biologics market include Genentech Inc., Biogen Idec, F. Hoffmann-La Roche AG, Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Ltd., Takeda Pharmaceutical Company Ltd. and Bristol-Myers Squibb.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Future Growth of Subcutaneous Biologics Market | Top Key Players – Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Ltd., Takeda Pharmaceutical Company Ltd here
News-ID: 1748251 • Views: 940
More Releases from Coherent Market Insights - Biotechnology
Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. Free Request Sample Copy
Diabetes Vaccine Market Scrutinized in New Research 2018-2026
Diabetes is one of most prevalent chronic diseases worldwide. According to WHO (World Health Organization), diabetes was one of top three leading causes of mortality in 2012. The diabetes vaccine currently under development has significant potential in younger age group (Below 20 years age), who are characterized by a stronger autoimmune response to combat infection from specific viruses. Diabetes vaccine is being developed to strengthen the body’s response against enterovirus
More Releases for Biologic
Biologic Injectors Market Insights, Forecast to 2028
Biologic injectors are the injecting devices used to deliver drugs and other substances for biological purposes. Biological products such as drugs, growth hormones, antibodies and other complex biological molecules are administered into the body of an organism through biologic injectors. Biologic injectors are basically used for the treatment of various diseases. Biologic injectors offer different methods of administration such as simple piston, gas, jet and others. They can also be used
Biologic and Medical Imaging Reagents: Global Healthcare Update 2018
Press Release – 10 Jan 2019 Research and Development News -- . . Latest Update "Biologic and Medical Imaging Reagents: Global Markets" with Industries Survey | Global Current Growth and Future. ' ' Report Highlights The global market for biological imaging reagents was valued at $13.2 billion in 2016. This market will grow from $14.4 billion in 2017 to nearly $23.9 billion by 2022 with a compound annual growth rate (CAGR) of 10.6% for the
Biologic Therapeutics Market Insights & Outlook on Industry 2025
Global Biologic Therapeutics Market: Snapshot The branch of science that deals with manufacturing medicines and pharmaceutical products based on biological origins is called biological therapeutics. Any pharmaceutical drug product manufactured from semi-synthesized and biological sources is included under this field. Owing to rapid advances experienced by this sector, a distinct biologic therapeutics market has formed. This market is mainly being driven by a rising demand for better healthcare treatments occurring all
Biologic Therapeutics Market Geographical Outlook by 2025
Global Biologic Therapeutics Market: Overview The global biologic therapeutics market is predicted to benefit from the rising applications of biological products. Biological products could be made of sugars, nucleic acids, proteins, or complex combinations of these substances, or may be living components such as cells and tissues. Biological products are used to prevent diseases, diagnose diseases, or treat or cure medical conditions. Global Biologic Therapeutics Market: Key Trends and Opportunities First and foremost,
Human Hepatitis B Immunoglobulin (IM) Market 2017 - Shanghai RAAS, Hualan Biolog …
Apex Research, recently published a detailed market research study focused on the "Human Hepatitis B Immunoglobulin (IM) Market" across the global, regional and country level. The report provides 360° analysis of "Human Hepatitis B Immunoglobulin (IM) Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Human Hepatitis B Immunoglobulin (IM) industry, and
Global Biologic Drugs Sales Market Report 2017
In this report, the global Biologic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Biologic Drugs for these regions, from 2012 to 2022 (forecast),